View active Spravato locations
Spravato vs ketamine
IV ketamine for depression uses ketamine by an intravenous infusion outside its FDA-approved anesthetic indication. This is an off-label treatment decision.
Ask whether the actual service is IV ketamine, nasal esketamine or another formulation, and where it can currently be provided. Confirm the responsible clinician, monitoring, emergency arrangements, written preparation instructions and appointment availability. Confirm that the selected site has a monitored infusion program and accepts your proposed treatment before arranging travel. If treatment is offered, ask how psychiatric follow-up, transport and side-effect advice are coordinated. Do not travel for an infusion until the site, order and practical arrangements are confirmed directly.
IV ketamine for depression uses ketamine by an intravenous infusion outside its FDA-approved anesthetic indication. This is an off-label treatment decision. It is different from Spravato, the nasal esketamine product with specific adult depression indications and a REMS. The two treatments differ in formulation, dose planning, monitoring requirements and insurance pathways. Ask whether IV treatment is currently offered and which location, clinician and monitored setting would provide it.
Ketamine affects NMDA receptors and other brain signalling systems. Its antidepressant mechanism is not fully understood. Research and guidelines support discussion of ketamine as an advanced option in selected difficult-to-treat depression cases, but a rapid response is not guaranteed. A strong subjective experience during an infusion does not establish lasting benefit.
A psychiatrist reviews the depressive illness, adequate previous treatment trials, current risk, other diagnoses and the alternatives. The assessment also reviews cardiovascular health, substance-use risks, pregnancy, liver history and medicines that may affect sedation or blood pressure. The clinician should explain why off-label IV ketamine is being considered and how outcomes and harms will be assessed. A suicidal crisis needs urgent safety care independently of a planned infusion.
Ask about the intended condition, expected benefit, uncertainty and alternatives such as established medicines, psychotherapy or a referral for brain stimulation. Off-label prescribing is a clinical decision. It does not mean FDA has approved a depression dose or schedule.
Ask who will administer and monitor the infusion, how breathing, blood pressure and alertness will be assessed, and how an emergency will be handled. Do not transfer onsite infusion information to an unsupervised home or compounded nasal regimen.
Before starting, agree on symptom and function measures, when benefit will be reviewed and what happens if there is little improvement or adverse effects. Session numbers and maintenance intervals must come from the treating program. They cannot be inferred from the Spravato label.
Bring the treatment history and a full medicine and substance-use list. Obtain the program’s written eating, drinking and medication instructions. Do not substitute the Spravato food rules for an infusion protocol. Arrange transport home and time away from driving and hazardous work. Ask about support after discharge, responsibilities later that day and whom to call about a concerning symptom.
Ketamine can cause sedation, dissociation, higher blood pressure and breathing problems. Misuse and dependence risks, urinary symptoms and other adverse effects require discussion, especially with repeated exposure. MedlinePlus advises no driving or machinery for at least 24 hours after ketamine injection. Follow any longer restriction from the treating clinician. Call 911 for breathing difficulty, fainting or a serious allergic reaction. Report urinary pain, troubling confusion or worsening mood to the treating clinician.
Track changes in mood, daily function, adverse effects and the duration of any improvement. If symptoms return between sessions, contact the treating psychiatrist rather than arranging an unsupervised dose increase. There is no Spravato-label maintenance schedule that can simply be applied to IV ketamine. A switch between formulations requires a new clinical and practical review.
Ask for a written estimate for assessment, infusion, monitoring and follow-up. Coverage of a psychiatry visit does not prove coverage of off-label ketamine. Confirm which services are submitted to insurance and which are self-pay before treatment. Confirm the actual infusion service, responsible clinician, supply and estimate before making treatment arrangements.
Nao Medical Hicksville: 232 W Old Country Rd, Hicksville, NY 11801. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
IV ketamine for depression is an off-label treatment and is different from the approved Spravato nasal spray. Start with an assessment of symptoms, earlier treatment and safety. Before an infusion, confirm the treating clinician, monitoring arrangements, appointment and transport plan with the service.
Spravato is the brand name for esketamine nasal spray. Its current US label covers treatment-resistant depression in adults, either on its own or with an oral antidepressant. A separate indication covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behaviour; that use requires an oral antidepressant. These indications should not be merged into one promise. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behaviour, and it does not replace hospitalization when that is needed.
Assessment reviews the diagnosis, previous treatments and whether they were taken at an adequate dose and duration. The clinician checks blood pressure, cardiovascular and cerebrovascular history, psychosis, substance-use risks, pregnancy and interacting medicines. Aneurysmal vascular disease, arteriovenous malformation, a history of intracerebral hemorrhage and hypersensitivity are labelled contraindications. Insurer criteria can differ from the clinical label.
Esketamine affects NMDA receptors in the brain. Its antidepressant mechanism is not fully understood. It differs from standard oral antidepressants and from IV ketamine. Feeling dissociated during a session is not a test of whether the depression treatment will work. The clinician judges benefit from symptoms, daily function and safety over time.
The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours associated with antidepressants in younger people. Do not drive, operate machinery or undertake activities requiring full alertness until the next day after a restful sleep. Arrange a ride home even if you feel ready to drive. Blood-pressure elevation can make a session unsuitable. Pregnancy may harm the fetus and breastfeeding is not recommended during treatment. Urgent worsening depression or a suicide crisis needs immediate clinical or emergency care rather than waiting for the next session.
Bring antidepressant names, doses, dates, response, adverse effects and relevant hospital records. Clarify whether the proposed treatment is TRD care or the separate acute suicidal MDD indication. Discuss other suitable treatments and continuing therapy.
Spravato is administered through its REMS in a certified healthcare setting. Patients self-administer the nasal spray under direct supervision. Blood pressure is checked before dosing, around 40 minutes afterwards and further as needed. Breathing is monitored, including pulse oximetry, for at least two hours. Release occurs only when the clinician finds the patient stable. Some visits take longer.
TRD treatment is twice weekly for the first four weeks, then weekly in weeks five through eight. From week nine, dosing is weekly or every two weeks according to response. The clinician assesses benefit after the initial four weeks. The acute suicidal MDD regimen is a separate twice-weekly four-week course. Longer use for that indication has not been systematically evaluated.
The boxed warning covers sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours associated with antidepressants in younger people. Do not drive, operate machinery or undertake activities requiring full alertness until the next day after a restful sleep. Arrange a ride home even if you feel ready to drive. Blood-pressure elevation can make a session unsuitable. Pregnancy may harm the fetus and breastfeeding is not recommended during treatment. Urgent worsening depression or a suicide crisis needs immediate clinical or emergency care rather than waiting for the next session.
Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.
The formulation and regulatory status differ, and insurers apply different benefits and authorization rules. Obtain a plan-specific determination and written estimate rather than relying on another patient’s claim history.
Contact the treating psychiatrist for reassessment of symptoms, safety and the treatment plan. Do not switch routes, increase frequency or add compounded ketamine yourself.
Patients in Hicksville can review nearby Nao Medical Spravato options below or start with the main Spravato treatment details for eligibility, insurance, and booking details.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
Hicksville is a strong option for central Nassau patients who want local access to monitored Spravato treatment close to home.
View Spravato details for Hicksville